Dexketoprofen trometamol

Drugs of the Future

Volumn 21, Issue 6, 1996, Pages 587-592

  Mauleón, David ^a  

^a Laboratories Menarini SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXKETOPROFEN; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHIRALITY; ENANTIOMER; ESTERIFICATION; GASTROINTESTINAL TOXICITY; INFLAMMATION; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; SHORT SURVEY;

EID: 0029946279     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.06.356766     Document Type: Short Survey

References (51)

1. Warneck, J., Wisdom, R.A. (Labs. Menarini SA). Arylalkanoic acid resolution. WO 9420633.
2. Carganico, G., Mauleón, D., García, L. (Labs. Menarini SA). New arylpropionic deriv., procedure for its preparation and use as analgesic. WO 9411332.
3. Veys, E.M. 20 Years' experience with ketoprofen. Scand J Rheumatol 1991, Suppl. 90: 3-44.
4. Caldwell, J., Hutt, A.J., Fournel-Gigleux, S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988, 37: 105-14.
5. Evans, A.M. Enantioselectivepharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992, 42: 237-56.
6. Vane, J.R., Botting, R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995, 44: 1-10.
7. Dray, A. Inflammatory mediators of pain. Brit J Anaesth 1995, 75: 125-31.
8. Muller, N., Payan, E., Lapicque, F., Bannwarth, B., Netter, P. Pharmacological aspects of chiral nonsteroidal antiinflammatory drugs. Fundam Clin Pharmacol 1990, 4: 617-34.
9. Williams, K.M. Enantiomers in arthritic disorders. Pharmacol Ther 1990, 46: 273-95.
10. Hayball, P.J., Nation, R.L., Bochner, F. Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: In vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992, 4: 484-7.
11. Yamaguchi, T., Hirose, K., Nakamura, Y., Sugeno, K. The inhibitory activities of 480156-S and its related compounds on prostaglandin synthetase. Folia Pharmacol Jpn 1987, 90: 295-302.
12. Suesa, N., Fernández, M.F., Gutiérrez, M., Rufat, M.J., Rotllán, E., Calvo, L., Mauleón, D., Carganico, G. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993, 5: 589-95.
13. Carabaza, A., Cabré, F., Rotllán, E., Gómez, M., Gutiérrez, M., García, L., Mauleón, D. Stereoselective inhibition of inducible cyclooxygenase by chiral non-steroidal anti-inflammatory drugs. J Clin Pharmacol 1996, in press.
14. Panara, M.R., Greco, A., Santini, G. et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Brit J Pharmacol 1995, 116: 2429-34.
15. Ferrer, X., Fernández, M.F., Calvo, L., Cama, C., Mauleón, D., Carganico, G. Antiinflammatory activity of S-(+)-ketoprofen in the carrageenan-induced paw edema of the rat. Meth Find Exp Clin Pharmacol 1994, 16(Suppl. 1): Abst P-22.
16. Woolf, C.J. A new strategy for the treatment of inflammatory pain. Prevention or elimination of central sensitization. Drugs 1994, 47: 1-9.
17. Cashman, J., McAnulty, G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use. Drugs 1995, 49: 51-70.
18. Neugebauer, V., Geisslinger, G., Rümenapp, P., Weiretter, F., Szelenyi, I., Brune, K., Schaible, H.G. Antinoceptive effects of R(-)- and S(-t-)-flurbiprofen on rat spinal dorsal horn neurons rendered hyperexcitable by an acute knee joint inflammation. J Pharmacol Exp Ther 1995, 275: 618-28.
19. Yaksh, T.L., Malmberg, A.B. Spinal actions of NSAIDs in blocking spinally mediated hyperalgesia: The role of cyclooxygenase products. Agents Actions 1993, 41(Suppl.): 89-100.
20. Brune, K., Menzel-Soglowek, S., Zeilhofer, H.U. Differential analgesic effects of aspirin-like drugs. Drugs 1992, 44: 52-9.
21. Fernández, M.F., Ferrer, X., Calvo, L., Cama, C., Mauleón, D., Carganico, G. Analgesic activity of S-(+)-ketoprofen in the abdominal pain induced by phenylbenzoquinone in the mouse. Meth Find Exp Clin Pharmacol 1994, 16(Suppl. 1): Abst P-24.
22. Calvo, L., Fernández, M.F., Ferrer, X., Ruiz, A., Cama, C., Mauleón, D., Carganico, G. Analgesic action of ketoprofen enantiomers in animal models. Pharmacol Res 1995, 31 (Suppl.): 257.
23. Calvo, L., Fernández, M.F., Ferrer, X., Ruiz, A., Mauleón, D., Carganico, G. Analgesic activity of ketoprofen enantiomers in the abdominal pain induced by intraperitoneal injection of etacrinic acid in the rat. Meth Find Exp Clin Pharmacol 1994, 16(Suppl. 1): Abst P-25.
24. Mauleón, D., Mis, R., Ginesta, J., Ortega, E., Vilageliu, J., Basi, N., Carganico, G. Pharmacokinetics of ketoprofen enantiomers in monkeys following single and multiple oral administration. Chirality 1994, 6: 537-42.
25. Iwakawa, S., He, X., Hashimoto, S., Volland, C., Benet, L.Z., Lin, E.T. Stereoselective disposition of ketoprofen in rats. Drug Metab Dispos 1991, 19: 717-8.
26. Mis, R., Ginesta, J., Ortega, E., Mauleón, D., Carganico, G. Pharmacokinetics of the enantiomer LM-1158 in the rat. Rev Farmacol Clin Exp 1992, Número Especial: Abst 52.
27. Aberg, G., Ciofalo, V.B., Pendleton, R., Ray, G., Weddle, D. Inversion of (P)- to (S)-ketoprofen in eight animal species. Chirality 1995, 7: 383-7.
28. Cochet, P., Bromet-Petit, M., Mis, R., Bromet, N., Carganico, G., Ortega, E. Quantitative tissue distribution of LM-1158 in Long-Evans rats after a single (5 mg/kg) oral administration. 5th Eur ISSX Meet (Sept 26-29, Tours) 1993.
29. McCormack, K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994, 59: 9-43.
30. Hayball, P.J., Nation, R.L., Bochner, F., Newton, J.L., Massy-Westropp, R.A., Hamon, D.P.G. Plasma protein binding of ketoprofen enantiomers in man: Method of development and its application. Chirality 1991, 3: 460-6.
31. Jamali, F., Russell, A.S., Foster, R.T., Lemko, C. Ketoprofen pharmacokinetics in humans: Evidence of enantiomeric inversion and lack of interaction. J Pharm Sci 1990, 79: 460-1.
32. Jamali, F., Brocks, D.R. Clinicalpharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990, 19: 197-217.
33. Foster, R.T., Jamali, F. Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. Drug Metab Dispos 1988, 16: 623-6.
34. Mayer, J.M. Stereoselective metabolism of anti-inflammatory 2-arylpropionates. Acta Pharm Nord 1990, 2: 197-216.
35. Soraci, A., Benoit, E. In vitro fenoprofenyl-coenzyme A thioester formation: Interspecies variations. Chirality 1995, 7: 534-40.
36. Reichel, C., Bang, H., Brune, K., Geisslinger, G., Menzel, S. 2-Arylpropionyl-CoA epimerase: Partialpeptide sequences and tissue localization. Biochem Pharmacol 1995, 50: 1803-6.
37. Carabaza, A., Suesa, N., Tost, D. et al. Stereoselective metabolic pathways of ketoprofen in the rat: Incorporation into triacylglycerols and enantiomeric inversion. Chirality 1996, 8: 163-72.
38. Mis, R., Tost, D., Ortega, E., Mauleón, D., Carganico, G. Bioinversion of ketoprofen enantiomers in several species. Meth Find Exp Clin Pharmacol 1994, 16(Suppl. 1): Abst P-21.
39. Gich, I., Bayés, M., Barbanoj, M.J., Artigas, R., Tost, D., Mauleón, D. Bioinversion of R-(-)-ketoprofen following oral administration in healthy volunteers. Clin Drug Invest 1996, 11(6): 347-52.
40. Williams, K., Day, R., Knihinicki, R., Duffield, A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986, 35: 3403-5.
41. Sallustio, B.C., Meffin, P.J., Knights, K.M. The stereospecific incorporation of fenoprofen into rat hepatocyte and adipocyte triacylglycerols. Biochem Pharmacol 1988, 37: 1919-23.
42. Gich, I., Barbanoj, M.J., Artigas, R., Mis, R., Bayés, M., Tost, D., Martin, S., Carganico, G., Mauleón, D. New fast-onset oral formulation of dexketoprofen. 6th Intersci World Conf Inflamm Antirheum Analg Immunomodul (March 28-30, Geneva) 1995, Abst 90.
43. Meryn, S. Nonsteroidal anti-inflammatory drugs and peptic ulcers - Mechanisms, risk factors and treatment. Clin Exp Rheumatol 1994, 12: 119-21.
44. Rainsford, K.D. Mechanisms of gastrointestinal toxicity of non-stemidal anti-inflammatory drugs. Scand J Gastroenterol 1989, 24(Suppl. 163): 9-16.
45. Fernández, M.F., Calvo, L., Mauleón, D., Carganico, G. Comparative gastric ulcerogenic activities of LM-1158 and racemic ketoprofen. Rev Farmacol Clin Exp 1992, Número Especial: Abst 73.
46. Bjarnason, I., MacPherson, A.J.S. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994, 62: 145-7.
47. Myllykangas-Luosujärvi, R., Aho, K., Isomäki, H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995, 22: 2214-7.
48. Wechter, W.J., Bigornia, A., Murray, E.D., Levine, B.H., Joung, J.W. Rac-flurbiprofen is more ulcerogenic than its S-enantiomer. Chirality 1993, 5: 492-4.
49. Wright, M.R., Davies, N.M., Jamali, F. Rationale for the development of stereochemically pure enantiomers: Are the R enantiomers of NSAIDs inactive? J Pharm Sci 1994, 83: 911-2.
50. Zapatero, M.I., Fernández, M.F., Cabré, F., Mauleón, D., Arañó, M.A. Gastrointestinal ulcerogenic effect of racemic ketoprofen and its enantiomers in the rat. V Congreso de Ciencias Farmacéuticas (Nov 15-18, Alcalá de Henares) 1995.
51. Planas, E., Gay, C., Donado, M., Martinez, J.M., Artigas, R., Torres, F., Mauleón, D., Carganico, G. Analgesic effect of low doses of dexketoprofen in the dental pain model: A randomised, double-blind, placebo-controlled study. Clin Drug Invest 1996, 11(6): 320-30.